You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Details for Patent: 7,851,482


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,851,482 protect, and when does it expire?

Patent 7,851,482 protects OPANA ER and is included in one NDA.

This patent has seventeen patent family members in twelve countries.

Summary for Patent: 7,851,482
Title:Method for making analgesics
Abstract: Improved analgesic oxymorphone hydrochloride contains less than 10 ppm of alpha, beta unsaturated ketones and pharmaceutical preparations comprising such oxymorphone hydrochloride. The oxymorphone hydrochloride is produced by reducing a starting material oxymorphone hydrochloride using gaseous hydrogen and under specified acidity, solvent system and temperature conditions. A specific polymorph of oxymorphone hydrochloride may be obtained by hydration.
Inventor(s): Dung; Jen-Sen (Boothwyn, PA), Keskeny; Erno M. (Wilmington, DE), Mencel; James J. (North Wales, PA)
Assignee: Johnson Matthey Public Limited Compnay (London, GB)
Application Number:11/866,840
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,851,482
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use; Process;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 7,851,482: A Comprehensive Analysis

Introduction

Patents are a cornerstone of intellectual property law, providing inventors and companies with exclusive rights to their innovations. The scope and claims of a patent are crucial in defining the boundaries of this exclusivity. This article will delve into the specifics of United States Patent 7,851,482, examining its scope, claims, and the broader patent landscape.

Background of the Patent

United States Patent 7,851,482, hereafter referred to as the '482 patent, is associated with pharmaceutical innovations, particularly in the context of Endo Pharmaceuticals Inc. vs. Actavis, Inc., a notable case involving patent licensing and infringement[2].

Patent Scope and Claims

Definition of Patent Scope

The scope of a patent is determined by its claims, which are the legally binding descriptions of the invention. The broader the claims, the wider the scope of protection, but this also increases the risk of challenges and litigation[3].

Claims Analysis of the '482 Patent

The '482 patent is characterized as being "completely unrelated to any of the previously licensed patents" in the context of the Endo Pharmaceuticals Inc. vs. Actavis, Inc. case. This indicates that the '482 patent has distinct claims that do not overlap with other licensed patents[2].

Claim Language and Scope

The language of the claims is critical. For instance, in the case of the '482 patent, the Federal Circuit opinion emphasized that the patent's claims do not cross-reference or claim priority to any of the licensed patents. This strict interpretation highlights the importance of precise claim drafting to avoid ambiguity and potential infringement disputes[1].

Patent Landscape and Licensing Agreements

Licensing Agreements and Covenant Not to Sue

Licensing agreements often include a covenant not to sue and a no implied rights provision. In the case of the '482 patent, the agreement did not cover this patent, indicating that it was not part of the licensed patents. This distinction is crucial as it affects the rights and obligations of the parties involved[1].

Implied License Arguments

The Federal Circuit has been clear in distinguishing between express and implied licenses. For the '482 patent, the court was unpersuaded by arguments of an implied license, emphasizing that no license agreement can confer rights the patentee does not have. This underscores the importance of explicit language in licensing agreements[1].

Patent Examination and Maintenance

Patent Examination Process

The examination process plays a significant role in shaping the scope of a patent. Research has shown that the examination process tends to narrow the scope of patent claims, particularly in terms of claim length and count. This narrowing can result in a higher probability of grant and a shorter examination process[3].

Patent Maintenance Payments

Patent maintenance payments are another indicator of patent scope. Patents with narrower claims at publication tend to have higher maintenance payments, suggesting a more focused and valuable invention[3].

International Patent Landscape

Global Patent Search Resources

In today's globalized world, understanding the international patent landscape is essential. Resources such as the USPTO's Patent Public Search, Global Dossier, and databases from other international intellectual property offices (like the European Patent Office and the World Intellectual Property Organization) provide comprehensive tools for searching and analyzing patents worldwide[4].

Cross-Border Patent Protection

Cross-border patent protection is critical for companies operating globally. The '482 patent, being part of a broader pharmaceutical portfolio, would need to be considered in the context of international patent laws and agreements to ensure comprehensive protection.

Case Law and Precedents

Endo Pharmaceuticals Inc. vs. Actavis, Inc.

The case involving the '482 patent highlights the importance of clear and specific claim language. The Federal Circuit's decision emphasized that the '482 patent was not covered by the licensing agreement, reinforcing the need for precise definitions in patent agreements[1].

TransCore and General Protecht Group Cases

Other cases, such as TransCore, LP v. Electronic Transaction Consultants Corp. and General Protecht Group, Inc. v. Leviton Manufacturing Co., Inc., provide precedents on the narrow category of conduct encompassing scenarios where a patentee has licensed or assigned a right and then sought to derogate from the right granted. These cases underscore the strict interpretation of patent claims and licensing agreements[1].

Key Takeaways

  • Clear Claim Language: The scope of a patent is defined by its claims, and clear, specific language is crucial to avoid disputes.
  • Licensing Agreements: Licensing agreements must be explicit about which patents are covered to avoid implied license arguments.
  • International Considerations: Global patent search resources and cross-border patent protection are essential for comprehensive IP management.
  • Patent Examination: The examination process can significantly narrow the scope of patent claims, impacting the patent's value and maintenance.
  • Case Law: Precedents from cases like Endo Pharmaceuticals Inc. vs. Actavis, Inc. and TransCore emphasize the importance of precise claim drafting and licensing agreements.

FAQs

Q: What is the significance of clear claim language in a patent?

A: Clear claim language is essential to define the scope of the patent and avoid ambiguity, which can lead to litigation and disputes.

Q: How does the patent examination process affect the scope of a patent?

A: The examination process tends to narrow the scope of patent claims, particularly in terms of claim length and count, which can result in a higher probability of grant and a shorter examination process.

Q: What is the difference between an express and an implied license in patent law?

A: An express license is explicitly granted in a licensing agreement, while an implied license is inferred from the actions or circumstances, which is generally not recognized by courts unless under very specific conditions.

Q: Why is international patent search important?

A: International patent search is crucial to ensure that an invention is not already patented elsewhere, providing comprehensive protection across different jurisdictions.

Q: How do maintenance payments reflect the scope of a patent?

A: Patents with narrower claims at publication tend to have higher maintenance payments, indicating a more focused and valuable invention.

Sources

  1. Endo Pharmaceuticals Inc. v. Actavis, Inc. & Endo Pharmaceuticals ... - JDSupra
  2. Endo Pharms. Inc. v. Actavis, Inc. (Fed Cir) - Robins Kaplan LLP
  3. Patent Claims and Patent Scope - SSRN
  4. Search for patents - USPTO - USPTO

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,851,482

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-001 Dec 9, 2011 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-002 Dec 9, 2011 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-003 Dec 9, 2011 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-004 Dec 9, 2011 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-005 Dec 9, 2011 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-006 Dec 9, 2011 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,851,482

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0624880.1Dec 14, 2006

International Family Members for US Patent 7,851,482

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007331223 ⤷  Subscribe
Brazil PI0720232 ⤷  Subscribe
Canada 2672644 ⤷  Subscribe
China 101652371 ⤷  Subscribe
China 102391271 ⤷  Subscribe
European Patent Office 2102213 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.